The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
The partnership also sets the stage for broader collaboration on rare disease treatments
The primary goal of the collaboration is joint research into trending and next-generation molecules
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
Subscribe To Our Newsletter & Stay Updated
